In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners.

The issue was carried out during the third quarter of 2022 as an issue of units, which brought the company approximately SEK 30.5 million before issue costs. Each unit contained four (4) shares and two (2) options of the subscription series TO1.

Added SEK 20.1 million to the company

All warrants (100%) in warrant series TO1 have now been converted to shares, which has added SEK 20.1 million to the company. The number of shares in the company after the conversion of the warrants amounts to 6,860,166 shares and the share capital amounts to SEK 3,430,083.

“The capital injection will primarily be used for our early research projects with focus on new innovative treatments for chronic inflammatory diseases where there is a pronounced medical need, but only few or no treatments.”

“We thank our shareholders for their support. The capital injection will primarily be used for our early research projects with focus on new innovative treatments for chronic inflammatory diseases where there is a pronounced medical need, but only few or no treatments,” says Sarah Fredriksson, CEO of Aqilion.

Photo of Sarah Fredriksson: Aqilion